Cytrellis Biosystems, a Boston, MA-based company developing a new class of non-surgical products to combat sagging skin associated with aging, received a strategic venture investment from Merz Pharma.
The amount of the deal was not disclosed.
Led by Doug Levinson, CEO and co-founder, Cytrellis Biosystems is a clinical stage company that has been developing an entirely new category of medical devices for the aesthetics market. Its proprietary technology removes excess skin without invasive surgery or scarring enabling physicians to improve sagging skin associated with aging on the face and other areas of the body.
Merz, which has joined other unnamed industry investors, recently launched its cvc arm focusing on the areas of anti-aging, skin rejuvenation and body shaping.
FinSMEs
28/04/2016